SEEING BLUES ALL AROUND
A CASE OF PROPYLTHIOURACIL-INDUCED CYANOPSIA
Keywords:
PROPYLTHIOURACIL-INDUCED CYANOPSIA, CYANOPSIA, PTUAbstract
INTRODUCTION/BACKGROUND
Cyanopsia is a subjective symptom characterized by a bluish appearance of the overall visual field and has been reported among patients taking phosphodiesterase-5 inhibitors. Propylthiouracil (PTU) is a member of the thiouracil group and widely used for the treatment of thyrotoxicosis. Despite being associated with various side effects, such as hepatitis, agranulocytosis, body rash, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, PTU-related cyanopsia has not been reported.
CASE
In this report, we describe a case of PTU-induced cyanopsia, including the results of biochemical laboratory tests. We also discuss treatment strategies and include literature review. A 33-year-old female presented with palpitations and tremors. Clinically, she appeared anxious with hand tremor and diffuse goiter. Her pulse was regular, and other systemic examinations were unremarkable. Thyroid function tests (TFTs) showed overt hyperthyroidism with suppressed thyroid-stimulating hormone (TSH) levels (<0.008 miu/L) and high free T4 levels (55.9 pmol/L). She was treated for Grave’s disease with carbimazole but developed significant urticaria. PTU was then introduced, but she developed a bluish appearance of her surrounding vision right after the second dose. The symptoms subsided after one day of discontinuing PTU. Re-challenging with PTU at a lower dose also resulted in a similar effect. Eye assessment by ophthalmology was normal. She was then given propranolol and cholestyramine to control her thyroid status. Definitive treatment with radioactive iodine will be administered once her thyroid function improves. PTU is one of the mainstay oral medications for hyperthyroidism and is generally well-tolerated. However, PTU-induced cyanopsia may limit oral treatment options, although the phenomenon appears reversible after stopping medication, regardless of the dose. It may cause significant distress and lead to discontinuation of treatment.
CONCLUSION
We report here, the first known case of PTU-induced cyanopsia.
Downloads
References
*
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Noor Hafis Md Tob, Chin Voon Tong, Joel Xiang Loong Lee, Siow Ping Lee, Melissa Vergis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.